Avenue Therapeutics
ATXI · OTC
$0.4042−$0.0258 (−6.00%)TodayMarket closed ·
No price history for this range.
EPS: actual vs estimate
Beat the estimate in 2 of the last 8 quarters, by 140.7% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q4 FY25 | $0.00 | -$0.22 | +0.0% |
| Q3 FY24 | -$0.9588 | -$1.92 | −100.3% |
| Q2 FY24 | -$1.07 | -$6.43 | −500.4% |
| Q1 FY24 | -$9.18 | -$15.40 | −67.8% |
| Q4 FY23 | -$7.65 | $4.50 | +158.8% |
| Q3 FY23 | -$19.89 | $4.50 | +122.6% |
| Q2 FY23 | -$22.18 | -$39.00 | −75.8% |
| Q1 FY23 | -$9.94 | -$101.25 | −918.1% |
Earnings calls
- Special Call - Avenue Therapeutics, Inc.
- ATXI - Avenue Therapeutics, Inc. (ATXI) CEO Dr. Lucy Lu Hosts Investor Update Call
- Avenue Therapeutics, Inc. (ATXI) InvaGen Announces Acquisition Agreement with Avenue Therapeutics Conference Call
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.